GlassScriptPhysician profile
Kelly A Stanton
NPI 1396429171
$2,028.63
in general payments reported to CMS, 2019-2025
20 companies · $964 in 2025
The $964 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $190 · 2024: $875 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.70 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $255.87 | 2024-2025 | |
| Atricure, INC. | $207.41 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Kiniksa Pharmaceuticals International, Plc | $172.37 | 2024 | Arcalyst |
| Abbott Laboratories | $147.04 | 2025 | Cardiomems |
| Novo Nordisk INC | $131.00 | 2025 | Wegovy |
| Pfizer INC. | $129.07 | 2024-2025 | |
| Amgen INC. | $128.34 | 2024-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $126.11 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $78.23 | 2024 | Xarelto |
| Heartflow, INC. | $59.06 | 2024-2025 | |
| Inspire Medical Systems, INC. | $38.23 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $38.21 | 2024-2025 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $36.26 | 2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $30.08 | 2025 | Onpattro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $27.22 | 2025 | Varithena Administration Pack |
| Kiniksa Pharmaceuticals, LTD. | $24.57 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $21.95 | 2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $15.40 | 2024 | |
| Glaxosmithkline, LLC. | $14.51 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Stanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.